Close Menu

Meridian Bioscience

NEW YORK (GenomeWeb News) — Meridian Bioscience today reported a 13 percent year-over-year increase in fiscal fourth quarter revenues and a 9 percent spike in full-year fiscal 2013 revenues.

NEW YORK (GenomeWeb News) – Meridian Bioscience today initiated sales and earnings guidance for its Fiscal Year 2014, while it reiterated prior guidance for full-year fiscal 2013.

NEW YORK (GenomeWeb News) – Meridian Bioscience said today that sales in its fiscal third quarter rose 12 percent year over year.

Bio-Rad has launched PrimePCR assays for Droplet Digital PCR.

Meridian Bioscience said this week that it has received US Food and Drug Administration clearance for Illumigene Mycoplasma, a molecular diagnostic test for Mycoplasma pneumoniae.

NEW YORK (GenomeWeb News) – Meridian Bioscience today announced the US Food and Drug Administration cleared its molecular diagnostic test for Mycoplasma pneumonia.

NEW YORK (GenomeWeb News) – Meridian Bioscience today reported essentially flat year-over-year sales growth for the second quarter, though adoption of its molecular diagnostic platform continued to accelerate.

Meridian Bioscience said this week that the US Food and Drug Administration has re-categorized its Illumigene Group A Streptococcus and Group B Streptococcus tests as moderate complexity under the Clinical Laboratory Improvement Amendments.

NEW YORK (GenomeWeb News) – Meridian Bioscience said on Monday that its illumigene Group A Streptococcus and illumigene Group B Streptococcus assays have been recategorized by the US Food and Drug Administration as "moderate complexity" tests under the Clinical Laboratory Improv

Cepheid's Xpert CT/NG assay for detecting Chlamydia trahcomatis and Neisseria gonorrhoeae is at least as accurate as two other commercially available molecular tests for the bacteria, according to the recently published results of the beta phase of a multi-center clinical

Pages

The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.

In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.

MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.

In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.